Einleitung
(→Einleitung) |
(→Foreword) |
||
| (667 dazwischenliegende Versionen von 5 Benutzern werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
{{DocumentPart}} | {{DocumentPart}} | ||
| − | = | + | =Foreword= |
| − | + | This is a supplement to the IHE Pathology | |
| − | + | and Laboratory Medicine Technical Framework V8.0. Each supplement undergoes a | |
| + | process of public comment and trial implementation before being incorporated | ||
| + | into the volumes of the Technical Frameworks. | ||
| − | + | This supplement was published on September 27, 2017 for Public Comment, with a comment period extending to mid-November. The current content is the Trial Implementation version, which has taken in consideration the comments received. | |
| − | + | This supplement describes changes to the | |
| + | existing technical framework documents. | ||
| − | + | “Boxed” instructions like the sample | |
| + | below indicate to the Volume Editor how to integrate the relevant section(s) | ||
| + | into the relevant Technical Framework volume. | ||
| − | + | <syntaxhighlight lang="xml"> | |
| + | Replace Section X.X by the following: | ||
| + | </syntaxhighlight> | ||
| − | + | Where the amendment adds text, make the added | |
| + | text '''bold underline'''. Where the amendment removes | ||
| + | text, make the removed text '''bold strikethrough'''. | ||
| + | When entire new sections are added, introduce with editor’s instructions to | ||
| + | “add new text” or similar, which for readability are not bolded or underlined. | ||
| − | + | General information about IHE can be found at: http://www.ihe.net. | |
| − | |||
| − | + | Information about the IHE Pathology and Laboratory Medicine domain can be found at: http://ihe.net/IHE_Domains. | |
| − | |||
| − | |||
| − | + | Information about the structure of IHE Technical Frameworks and Supplements can be found at: http://ihe.net/IHE_Process and http://ihe.net/Profiles. | |
| − | |||
| − | + | The current version of the IHE Technical Framework (if applicable) can be found at: http://ihe.net/Technical_Frameworks. | |
| − | |||
| − | + | ''Comments may be submitted on IHE Technical Framework templates any time at http://ihe.net/ihetemplates.cfm. Please enter comments/issues as soon as they are found. Do not wait until a future review cycle is announced.'' | |
| − | |||
| + | =Acknowledgements= | ||
| − | + | Following authors mainly contributed to this document: | |
| + | *Francois Macary, PHAST, Paris | ||
| + | *Dr. Gunter Haroske, Federal Association of German Pathologists, Berlin | ||
| + | *Dr. Frank Oemig, Deutsche Telekom Healthcare Solutions GmbH, Bonn | ||
| + | *Dr. Riki Merrick, APHL, San Francisco | ||
| + | *Dr. Raj Dash, Duke University, Durham | ||
| + | |||
| + | They have to acknowledge the contributions of Dr. Kai U. Heitmann, who managed the cooperation between PaLM and ART-DECOR. It was the very first time that a complete IHE TF document could be developed by means of the ART-DECOR tools and a media wiki. | ||
| + | |||
| + | __TOC__ | ||
| + | |||
| + | =Introduction to this Supplement= | ||
| + | |||
| + | This supplement complements volume 1 of | ||
| + | the PaLM technical framework with the description of the APSR 2.0 content | ||
| + | profile, and volume 3 with the bindings, content modules and value sets, which specify | ||
| + | this profile. | ||
| + | |||
| + | ==Open Issues and Questions== | ||
| + | |||
| + | ''None yet'' | ||
| + | |||
| + | ==Closed Issues== | ||
| + | |||
| + | '''APSR-07 – Representing the hierarchy of specimens in an entry''' : This APSR | ||
| + | supplement enables to represent the hierarchy of specimens at the CDA level 3. | ||
| + | The operations on specimen and production of child specimens are tracked in the | ||
| + | “Procedure Steps” section, which has a level 3 entry. | ||
| + | |||
| + | '''APSR-10 – Observation related to multiple specimens''': For example tumor staging may require combining data from multiple specimens (e.g., a breast excision with positive margins followed by a re-excision with clear margins – in this case the tumor size may be a composite of measurements from both specimens. Another example is staging of ovarian carcinomas with multiple biopsies of pelvis, peritoneum, nodes, omentum, etc.). To accommodate these use | ||
| + | cases, each problem organizer as well as each observation may reference any number of specimens using the <specimen> child element. Each of these references may point to a detailed description of the specimen, in the "procedure steps" section. | ||
| + | |||
| + | '''APSR-11 – Derivative specimens''':Specimens | ||
| + | derived from primary specimens for ancillary studies, which may be sent to a | ||
| + | reference lab or done in another part of the same institution, are included in | ||
| + | the scope of this profile. The results produced on a derived specimen are | ||
| + | attached to this specimen in the report. | ||
Aktuelle Version vom 7. Februar 2018, 11:17 Uhr
Dieses Material ist Teil des Leitfadens Pathologiebefund.
|
Foreword
This is a supplement to the IHE Pathology and Laboratory Medicine Technical Framework V8.0. Each supplement undergoes a process of public comment and trial implementation before being incorporated into the volumes of the Technical Frameworks.
This supplement was published on September 27, 2017 for Public Comment, with a comment period extending to mid-November. The current content is the Trial Implementation version, which has taken in consideration the comments received.
This supplement describes changes to the existing technical framework documents.
“Boxed” instructions like the sample below indicate to the Volume Editor how to integrate the relevant section(s) into the relevant Technical Framework volume.
Replace Section X.X by the following:
Where the amendment adds text, make the added text bold underline. Where the amendment removes text, make the removed text bold strikethrough. When entire new sections are added, introduce with editor’s instructions to “add new text” or similar, which for readability are not bolded or underlined.
General information about IHE can be found at: http://www.ihe.net.
Information about the IHE Pathology and Laboratory Medicine domain can be found at: http://ihe.net/IHE_Domains.
Information about the structure of IHE Technical Frameworks and Supplements can be found at: http://ihe.net/IHE_Process and http://ihe.net/Profiles.
The current version of the IHE Technical Framework (if applicable) can be found at: http://ihe.net/Technical_Frameworks.
Comments may be submitted on IHE Technical Framework templates any time at http://ihe.net/ihetemplates.cfm. Please enter comments/issues as soon as they are found. Do not wait until a future review cycle is announced.
Acknowledgements
Following authors mainly contributed to this document:
- Francois Macary, PHAST, Paris
- Dr. Gunter Haroske, Federal Association of German Pathologists, Berlin
- Dr. Frank Oemig, Deutsche Telekom Healthcare Solutions GmbH, Bonn
- Dr. Riki Merrick, APHL, San Francisco
- Dr. Raj Dash, Duke University, Durham
They have to acknowledge the contributions of Dr. Kai U. Heitmann, who managed the cooperation between PaLM and ART-DECOR. It was the very first time that a complete IHE TF document could be developed by means of the ART-DECOR tools and a media wiki.
Inhaltsverzeichnis
Introduction to this Supplement
This supplement complements volume 1 of the PaLM technical framework with the description of the APSR 2.0 content profile, and volume 3 with the bindings, content modules and value sets, which specify this profile.
Open Issues and Questions
None yet
Closed Issues
APSR-07 – Representing the hierarchy of specimens in an entry : This APSR supplement enables to represent the hierarchy of specimens at the CDA level 3. The operations on specimen and production of child specimens are tracked in the “Procedure Steps” section, which has a level 3 entry.
APSR-10 – Observation related to multiple specimens: For example tumor staging may require combining data from multiple specimens (e.g., a breast excision with positive margins followed by a re-excision with clear margins – in this case the tumor size may be a composite of measurements from both specimens. Another example is staging of ovarian carcinomas with multiple biopsies of pelvis, peritoneum, nodes, omentum, etc.). To accommodate these use cases, each problem organizer as well as each observation may reference any number of specimens using the <specimen> child element. Each of these references may point to a detailed description of the specimen, in the "procedure steps" section.
APSR-11 – Derivative specimens:Specimens derived from primary specimens for ancillary studies, which may be sent to a reference lab or done in another part of the same institution, are included in the scope of this profile. The results produced on a derived specimen are attached to this specimen in the report.
